TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01373762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Videogame Bikes
Description: The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Videogame Bikes
Description: The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
Study: NCT05403099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: immediate placement of dental implant after topical application of hyaluronic acid on implant surface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant placement
Description: immediate placement of dental implant without application of hyaluronic acid on implant surface
Study: NCT03403322

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesio taping
Description: An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesio taping
Description: An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.

Intervention type: OTHER
Group type: OTHER
Intervention: Without taping
Description: Children performed functional activities without tape

Intervention type: OTHER
Group type: OTHER
Intervention: Without taping
Description: Children performed functional activities without tape
Study: NCT04499300

Intervention type: OTHER
Intervention: Data collection from medical files
Description: Data collection from medical files

Intervention type: OTHER
Intervention: Data collection from medical files
Description: Data collection from medical files
Study: NCT04909580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision coaching with a patient decision aid
Description: Decision coaching guided by the Ottawa Decision Support Framework
Study: NCT00404495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles
Study: NCT04108000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT-Dementia
Description: The interventionist will begin the SPIRIT-dementia session by assessing the patient's and surrogate's cognitive, emotional, and spiritual/religious representations of the patient's illness, prognosis, and end-of-life care. Individualized information will be provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the patient will examine their values about life-sustaining treatment at the end of life. The interventionist will help the surrogate prepare for end-of-life decision-making and for the emotional burden of decision-making. A Goals-of-Care document will be completed at the end of the session. The delivery of SPIRIT-dementia incorporates enhanced consent techniques, such as reducing information load by proceeding in manageable segments, offering repetition of material, opportunity for rehearsal, and using targeted questioning to verify adequate comprehension prior to eliciting preferences for goals of care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: As required by Centers for Medicare and Medicaid Services (CMS) written information on advance directives is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an advance directive.
Study: NCT04152265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires
Description: complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)

Intervention type: OTHER
Group type: OTHER
Intervention: demographic data collections
Description: completing the demographic questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: anthropometric data collections
Description: For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collecte the biological samples
Description: blood and faeces collections
Study: NCT01948635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tapered PVC-cuffed tracheal tubes
Description: Patients will be intubated with tapered-shape tracheal tubes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVC-cuffed tracheal tube
Description: Patients will be intubated with standard PVC cuffed tracheal tubes
Study: NCT01292070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal Human Fcγ1-Fel d1 fusion protein
Description: Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of \>= to 10mm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Positive Control - standardized cat hair allergenic extract (CAT)
Description: 4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Positive Control - Histamine Prick
Description: 1.0 mg/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Negative Control - Intradermal Diluent
Description: Saline, Albumin with Phenol (HSA) sterile diluent
Study: NCT02519101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous noninvasive blood pressure monitoring ClearSight-Device
Description: Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
Study: NCT04997707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Abbott
Description: in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Abbott
Description: in a rate of 75-100 μg/kg/min in P group, and 25μg/kg/min in BA group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Inhalation Solution
Description: in BA group will be calculated by age-adjusted end - tidal MAC as follows: for age of 18-25 years, 26-40 years and ≥40 years MAC will be 2.6%, 2.2% and 1.8% respectively then final concentration to be delivered will be 0.2% lower than calculated half MAC.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: transcranial motor evoked potential(Tcm
Description: using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: transcranial motor evoked potential(Tcm
Description: using NIM-SPINE™ SYSTEM (2005 Medtronic Sofamor Danek USA, Inc.). The stimulation used is a train-of-five square wave stimulation, 2ms inter-stimulus interval, 500 μs width and 40-220 mA intensity which can be increased with 10 mA steps till muscle answer potential is recorded.
Study: NCT04858919

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D transabdominal ultrasound
Description: Initially 3D pelvic ultrasound will be performed on all patients. The transabdominal probes used will be those of the ultrasound scanner using a convex probe (multiple frequency 1-6 MHz).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: transrectal ultrasound
Description: The vaginal probe will be covered with the customary plastic sheath and richly lubricated with lubricating gel. The probe will then be slowly advanced into the rectum. The transvaginal probes used will be those of the ultrasound scanner using a vaginal probe (multiple frequency 1-8 MHz). The scanning technique will be similar to that of Transvaginal ultrasound.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: vaginoscopy
Description: It is the final procedure in the study to reach the accurate diagnosis. A rigid hysteroscope will be used. The sheath has a 5-mm outer diameter, with 2.9 mm rod lens. A high intensity light source and fiberoptic cable will be used to illuminate the uterine cavity. A solution of 0.9% normal saline will be used as the distention medium. The pressure will be kept at 100-120 mmHg using a pressure adjustable cuff system with the aim of maintaining the lowest pressure required to distend the uterine cavity.
Study: NCT01330810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
Study: NCT04599387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Exercise Prescription
Description: Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
Study: NCT04092959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
Study: NCT04487067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV Q3W
Study: NCT03584620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band
Study: NCT02007005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abnobaVISCUM Fraxini
Description: intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
Study: NCT02969525

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosage regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosage regimens.
Study: NCT04272775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study: NCT02969525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosage regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosage regimens.
Study: NCT03445065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eversense XL CGM System
Description: The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense XL CGM System
Description: The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eversense XL CGM System
Description: The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense XL CGM System
Description: The Eversense XL Continuous Glucose Monitoring (CGM) System consists of an implantable sensor inserted under the skin, an external transmitter, and a Mobile Medical Application (MMA) for display of glucose information that runs on a Handheld Device (HHD).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual SMBG or FGM device used by participants
Description: Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual SMBG or FGM device used by participants
Description: Commercially available products in France for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM) were considered as comparators for this study.
Study: NCT04386525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil
Description: soft gels,1000gm, 84% of DHA and EPA
Study: NCT04504656

Intervention type: OTHER
Intervention: observation of postoperative leak, stenosis, mortality
Description: detect complications in both groups

Intervention type: OTHER
Intervention: observation of postoperative leak, stenosis, mortality
Description: detect complications in both groups
Study: NCT04180644

Intervention type: OTHER
Intervention: Skin tape strips
Description: Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.

Intervention type: OTHER
Intervention: Skin tape strips
Description: Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.
Study: NCT04537468

Intervention type: OTHER
Group type: OTHER
Intervention: Skin squame collection
Description: Subjects underwent skin squame collection by scraping. The investigator gently scraped the surface of a lesional skin area for patients with psoriasis, and of a non-lesional skin area for healthy volunteers to collect superficial cells. These samples were analyzed by gene expression analyses.

Intervention type: OTHER
Group type: OTHER
Intervention: Tape strip collection
Description: The first subjects had up to 35 tape strips from a maximum of 4 areas (4 X 35 strippings) on the trunk or limbs (excluding the genital area). Patients with atopic dermatitis or psoriasis had tape stripping performed on lesional skin areas and the control subjects had tape stripping performed on nonlesional skin areas. The next subjects were used to determine the optimal number of tape strips required to obtain a good signal by gene expression analyses.

Intervention type: OTHER
Group type: OTHER
Intervention: Tape strip and skin biopsy collection
Description: Subjects had tape stripping on up to 3 different skin areas (2 areas on lesional skin and one area of nonlesional skin for patients with atopic dermatitis or psoriasis, and 2 areas of healthy skin for control subjects) using the optimal number of tape strips, as determined in the previous part. One 4-mm skin biopsy on a tape stripped area plus one 4-mm biopsy on non-tape-stripped skin (2 biopsies per subject) were also collected.
Study: NCT00118898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine
Description: 600 mg abacavir/300 mg lamivudine tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine
Description: 600 mg abacavir/300 mg lamivudine tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 300 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine placebo
Description: Placebo tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine placebo
Description: Placebo tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate placebo
Description: Placebo tablet taken orally daily
Study: NCT04272775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study: NCT00118898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate placebo
Description: Placebo tablet taken orally daily